US Patent

US9895422 — Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders

Method of Use · Assigned to Veroscience LLC · Expires 2030-06-07 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating a metabolic disorder using a combination of a dopamine agonist and a first-phase insulin secretagogue.

USPTO Abstract

The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.

Drugs covered by this patent

bromocriptine-mesylate (BROMOCRIPTINE MESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2285`	—	bromocriptine-mesylate

Patent Metadata

Patent number: US9895422
Jurisdiction: US
Classification: Method of Use
Expires: 2030-06-07
Drug substance claim: No
Drug product claim: No
Assignee: Veroscience LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.